COVID-19 vaccine makers have reached unprecedented scale in the manufacture of vaccines over the past year. Manufacturers are now producing about 1.5 billion doses per month globally. Most of the vaccines making up this total have received emergency authorization by either a Stringent Regulatory Authority (SRA) or Emergency Use Listing (EUL) from the WHO, though some (including Novavax) are still in the review process.
Projections indicate that there will be approximately 11 billion doses by the end of 2021 and more than 20 billion doses produced in 2022. As a result, there will be enough doses available to reach the 40 percent target by the end of 2021, even taking into consideration the expanding child eligibility and booster campaigns in some high and upper-middle income countries. Similarly, there will be sufficient doses manufactured before mid-2022 to meet the 70 percent target in all countries (Tab 2).
Source: Manufacturing projection data from Launch and Scale Speedometer, an initiative of the Duke Global Health Innovation Center (November 15, 2021)
